SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Facade of AstraZeneca's office in Shanghai, China
FDA
AstraZeneca Gets Full FDA Approval for CMS-Selected Lymphoma Treatment
The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the 15 products to be subject to IRA-prescripted price negotiations for Medicare this year.
January 17, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Photo of a GLP-1 injector pen on a blue background
glp-1
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
The data suggest the high dose nearly closes the efficacy gap with Zepbound.
January 17, 2025
 · 
3 min read
 · 
Nick Paul Taylor
Halftone collage banner, palm and magic glass ball floating in the air on a dark background. Magic clouds, stars, pop art poster.
Deals
The Biopharma Crystal Ball Comes Out at JPM25
Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea for the slow, healthy recovery of the industry at large.
January 17, 2025
 · 
3 min read
 · 
Annalee Armstrong
A piggy bank crammed with $100 bills on a background of American cash
Drug pricing
Novo’s Ozempic, Wegovy Targeted in Second Round of IRA Drug Price Negotiations
Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare negotiations or not. CMS has until June 1 to send an initial offer for the adjusted prices.
January 17, 2025
 · 
3 min read
 · 
Tristan Manalac
Amgen sign at its headquarters in Thousand Oaks, California, USA.
Approvals
Looking Beyond Obesity, Amgen Wins Colorectal Cancer Expansion for Lumakras
The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic colorectal cancer, but in its approval announcement, the FDA pointed to significant improvements in progression-free survival, calling it the “major efficacy outcome” of the trial.
January 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Novartis' office building in Marburg, Germany
Patents
Novartis Scrambles to Squelch Copycats as Generics Gain Ground
Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto.
January 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Boehringer Ingelheim sign on a building/
Schizophrenia
Boehringer Suffers Phase III Schizophrenia Fail, Legal Parry by HHS
Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and Human Services hit back on the pharma’s legal challenge to the IRA’s drug price negotiation program.
January 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Human hands holding colorful puzzle pieces in 80s retro collage vector illustration. Mixed media artwork for concept of cooperation, teamwork, partnership and successful solutions.
Editorial
The People Behind Biopharma’s Big Wins: Personal Stories From JPM25
As I ran from interview to interview across San Francisco, I was consistently warmed by the stories I was told by biotech and pharma executives—and the general comradery in the air throughout the chaotic event.
January 17, 2025
 · 
4 min read
 · 
Annalee Armstrong
Pictured: Exterior view of the headquarters of the
Complete response letters
Manufacturing Issues Result in FDA Rejection of Atara’s Cell Therapy
Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market just yet, forcing the company to “significantly reduce expenses.”
January 16, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS